(Q35870214)

10 August 2017

Clinical characteristics of progressive relapsing multiple sclerosis (English)

1 reference

progressive relapsing multiple sclerosis

10 August 2017

0 references

4

G R Cutter

0 references

author name string

M J Tullman

series ordinal

1

1 reference

PubMed ID

15327045

10 August 2017

R J Oshinsky

series ordinal

2

1 reference

PubMed ID

15327045

10 August 2017

F D Lublin

series ordinal

3

1 reference

10 August 2017

1 August 2004

1 reference

Multiple Sclerosis Journal

10 August 2017

1 reference

10 August 2017

10

1 reference

10 August 2017

4

1 reference

10 August 2017

451-454

1 reference

Defining the clinical course of multiple sclerosis: Results of an international survey

10 August 2017

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1059OA

Multiple sclerosis that is progressive from the time of onset: clinical characteristics and progression of disability

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1059OA

The natural history of multiple sclerosis: a geographically based study. 7. Progressive-relapsing and relapsing-progressive multiple sclerosis: a re-evaluation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1059OA

Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1059OA

The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1059OA

Clinical study of primary progressive multiple sclerosis in Northern Ireland, UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1059OA

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1059OA

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1059OA

The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1059OA

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1059OA

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1059OA

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1059OA

Effect of relapses on development of residual deficit in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1059OA

The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1059OA

Primary progressive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1059OA

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1059OA

10.1191/1352458504MS1059OA

21 January 2018

Identifiers

DOI

1 reference

10 August 2017

1 reference

PubMed ID

15327045